Monthly Archives: September 2018

GILEAD DEFENDS THEIR SOFOSBUVIR PATENT SUCCESSFULLY

GILEAD DEFENDS THEIR SOFOSBUVIR PATENT SUCCESSFULLY

Sofusbovir is a substance from the group of nucleotide prodrugs, which has been successfully marketed by the US pharmaceutical company Gilead since 2013 as a medicament under the brand name „SOVALDI“. Sofosbuvir inhibits the RNA-dependent enzyme NS5B polymerase, which plays an important role in the replication of specific viruses. Thus, the substance is effective against ... Read More